PrismMarketView Profile Banner
PRISM MarketView Profile
PRISM MarketView

@PrismMarketView

Followers
5K
Following
315
Media
4K
Statuses
11K

The PRISM stock indexes track small/micro-cap companies across a diverse spectrum of industries including clean energy, biotech and next-gen tech.

New York, NY
Joined May 2020
Don't wanna be here? Send us removal request.
@PrismMarketView
PRISM MarketView
2 hours
$JANX reported Q3 2025 results with $989M in cash, positioning the company for key data readouts on JANX007 and JANX008 in December and continued pipeline progress into 2026. https://t.co/j8ZdWscWYF
0
0
0
@PrismMarketView
PRISM MarketView
7 hours
.@espn $DIS Teams Up with @DraftKings $DKNG for Exclusive Sports Betting Partnership After Ending Deal with PENN https://t.co/OdpykUbbH3
0
1
0
@PrismMarketView
PRISM MarketView
8 hours
(NASDAQ: $ABAT) American Battery Technology Company is EPA-approved to recycle about 100,000 damaged lithium-ion battery modules from the largest U.S. cleanup after a 2025 fire, using its upgraded Nevada facility to recover valuable materials like lithium and cobalt, with an
Tweet card summary image
prismmarketview.com
American Battery Technology Company (NASDAQ: ABAT), an integrated critical materials manufacturer and recycler, has been approved by the U.S. Environmental Prot
0
1
4
@PrismMarketView
PRISM MarketView
8 hours
(NASDAQ: $CCLD) @CareCloud reported strong Q3 2025 results with $31.1 million revenue (up 9% YoY), $3.1 million GAAP net income, and $7.7 million adjusted EBITDA, raising full-year revenue guidance to $117–$119 million. https://t.co/9jS1qqiQez
Tweet card summary image
prismmarketview.com
CareCloud, Inc. (Nasdaq: CCLD), a leader in healthcare technology and generative AI solutions, announced strong third quarter 2025 results, highlighted by highe
0
0
0
@PrismMarketView
PRISM MarketView
9 hours
(NYSE: $JNJ) Johnson & Johnson’s Caplyta (lumateperone) gained FDA approval as an add-on therapy for adults with major depressive disorder, showing strong efficacy and a favorable safety profile with minimal side effects, offering a promising new treatment option for the large
0
0
0
@PrismMarketView
PRISM MarketView
9 hours
.@WeRide_ai became the world’s first publicly traded robotaxi company with a dual listing in Hong Kong (HKEX: https://t.co/2yNBrDUyth) and on Nasdaq ( $WRD), raising over $300 million to expand its global autonomous fleet and accelerate commercialization, but shares dropped about
0
0
0
@PrismMarketView
PRISM MarketView
9 hours
Texas voters approved Proposition 4, authorizing a historic $20 billion investment over 20 years to modernize the state’s water infrastructure. https://t.co/nHcbcnNIsp
Tweet card summary image
prismmarketview.com
In a landmark move for infrastructure and environmental resilience, Texas voters have approved Proposition 4, authorizing up to $20 billion in long-term investm
0
0
0
@PrismMarketView
PRISM MarketView
10 hours
$CHPT expands its public sector reach with a new Sourcewell contract, streamlining EV charging deployment for up to 50,000 public agencies across the U.S. and Canada. The award reinforces ChargePoint’s leadership in government EV infrastructure.
Tweet card summary image
prismmarketview.com
ChargePoint Holdings, Inc., together with its subsidiaries, provides electric vehicle (EV) charging networks and charging solutions in the North America and Eur
0
0
1
@PrismMarketView
PRISM MarketView
11 hours
Trump Set to Announce Deal to Offer Weight Loss Drugs for $149 on TrumpRX $NVO $LLY $DJT https://t.co/YcTPgFsqTv
0
0
0
@PrismMarketView
PRISM MarketView
11 hours
PRISM Mid-Day Movers: Pharmaceuticals and Cannabis Lead Today’s Index’s @HepionPharma (NASDAQ: $HEPA) rose nearly 29%, and cannabis firm Fluent holding steady as it prepares for its Q3 earnings report. @fluentcannabis , Inc. (NASDAQ: $CNMTF) leads the cannabis index today
0
0
0
@PrismMarketView
PRISM MarketView
12 hours
(NASDAQ: $GH) @GuardantHealth's new study validates its Reveal™ blood test for early and accurate monitoring of chemotherapy response in advanced breast cancer, showing 100% sensitivity and specificity in detecting recurrence, and offering oncologists a powerful non-invasive
0
1
0
@PrismMarketView
PRISM MarketView
13 hours
$QNRX reported strong Q3 progress with FDA Orphan Drug Designation for QRX003, $105.3M financing, and expansion of its clinical programs. Recruitment for pivotal Netherton Syndrome trials is expected to begin in Q4 2025. https://t.co/sh0h5lhOEm
0
0
1